InSILC

InSilc

‌‌

Abstract

The aim of InSilc: In-silico trials for drug-eluting BVS development and evaluation is to develop an in-silico clinical trial (ISCT) platform for designing, developing and assessing drug-eluting bioresorbable vascular scaffolds (BVS), through building on the comprehensive biological and biomedical knowledge and advanced modelling approaches, towards simulating their implantation performance in the individual cardiovascular physiology.

The InSilc platform is based on the extension of existing multidisciplinary and multiscale models for mechanical behaviour, deployment and degradation, fluid dynamics, in the micro– and macroscale, and myocardial perfusion for predicting the drug-eluting BVS and vascular wall interaction, in the short– and medium/long term.

Consortium

Foundation for Research and Technology Hellas (Coordinator), The University Of Sheffield, Erasmus Universitair Medisch Centrum Rotterdam, POLITECNICO DI MILANO, Consiglio Nazionale Delle Ricerche, Mediolanum Cardio Research SRL, Feops Nv, NUI Galway, Istrazivacko Razvojni Centar Za Bioinzenjering Bioirc Doo, Panepistimio Ioanninon, CBSET INC, Boston Scientific LTD.

For more information visit InSilc